Brainstorm signs definitive agreement with mayo clinic for als
clinical trial and nurown manufacturing
New york & petach tikvah, israel--(business wire)--brainstorm cell therapeutics (otcqb: bcli), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the mayo clinic in rochester, minnesota to conduct its phase ii clinical trial of nurown™ in amyotrophic lateral sclerosis (als), pending fda approval. in addition, mayo's human cell therapy laboratory will manufacture the nurown cells for their clinical trial participants. the other two sites slated for the multi-center trial are the university of massachusetts memorial hospital and massachusetts general hospital. "we are delighted to be progressing further with our preparations for the trial and honored to be collaborating with professor anthony windebank and the mayo clinic," said chaim lebovits, president of brainstorm. mayo clinic is one of the largest stem cell clinical trial centers worldwide, with 27 trials currently in phase i. "brainstorm's mesenchymal stem cell-based approach is very compatible with some of the research conducted in our center," commented anthony windebank, m.d., professor of neurology and principal investigator of the study. "this trial is a logical next step in developing novel treatments for als which is a terrible disease with no effective treatment for our patients and their families." about brainstorm cell therapeutics, inc.brainstorm cell therapeutics inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. the company holds the rights to develop and commercialize its nurown technology through an exclusive, worldwide licensing agreement with ramot, the technology transfer company of tel aviv university. for more information, visit the company’s website at www.brainstorm-cell.com. safe harbor statementstatements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause brainstorm cell therapeutics inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. terms and phrases such as “may”, “should”, “would”, “could”, “will”, “expect”, “likely”, “believe”, “plan”, “estimate”, “predict”, “potential”, and similar terms and phrases are intended to identify these forward-looking statements. the potential risks and uncertainties include, without limitation, risks associated with brainstorm's limited operating history, history of losses; minimal working capital, dependence on its license to ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in brainstorm's annual report on form 10-k and quarterly reports on form 10-q available at http://www.sec.gov. these factors should be considered carefully, and readers should not place undue reliance on brainstorm’s forward-looking statements. the forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. we do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management’s beliefs, expectations or opinions should change, unless otherwise required by law. although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
